PepGen (PEPG) Return on Capital Employed (2022 - 2026)
PepGen (PEPG) reported Return on Capital Employed of 52.03% for Q1 2026, up 4002.0% on a YoY basis from 1.27% in Q1 2025, and up 5.89% sequentially from 55.28% in Q4 2025.
PepGen (PEPG) Return on Capital Employed (2022 - 2026) Analysis & Trends
PepGen (PEPG) has 5 years of Return on Capital Employed data on file, last reported at 52.03% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 4002.0% year-over-year to 52.03%; the trailing twelve-month figure through Mar 2026 stood at 52.03% (up 4002.0% YoY), and the FY2025 full-year result was 62.51%, up 1251.0% from the prior year.
- Return on Capital Employed improved to 52.03% in Q1 2026, from 55.28% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 28.26% in Q1 2022 to a low of 104.38% in Q2 2025.
- A 5-year average of 54.53% and a median of 53.32% in 2023 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed slumped 5060 bps in 2025 and soared 4002 bps in 2026, its largest moves.
- Tracing PEPG's Return on Capital Employed over 5 years: stood at 35.18% in 2022, then plunged by 77 bps to 62.27% in 2023, then dropped by 9 bps to 67.94% in 2024, then rose by 19 bps to 55.28% in 2025, then increased by 6 bps to 52.03% in 2026.
- Business Quant data shows PEPG's Return on Capital Employed at 52.03% in Q1 2026, 55.28% in Q4 2025, and 73.59% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | PepGen | 145.09 Mn | 145.09 Mn | - | -52.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -52.03% |
| Dec 31, 2025 | -55.28% |
| Sep 30, 2025 | -73.59% |
| Jun 30, 2025 | -104.38% |
| Mar 31, 2025 | -92.04% |
| Dec 31, 2024 | -67.94% |
| Sep 30, 2024 | -57.07% |
| Jun 30, 2024 | -53.78% |
| Mar 31, 2024 | -52.84% |
| Dec 31, 2023 | -62.27% |
| Sep 30, 2023 | -53.32% |
| Jun 30, 2023 | -43.49% |
| Mar 31, 2023 | -37.88% |
| Dec 31, 2022 | -35.18% |
| Sep 30, 2022 | -28.56% |
| Jun 30, 2022 | -29.13% |
| Mar 31, 2022 | -28.26% |